Kyongbo Pharmaceutical Co Ltd
KRX:214390
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (37.3), the stock would be worth ₩3 171.64 (53% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 80.2 | ₩6 820 |
0%
|
| 3-Year Average | 37.3 | ₩3 171.64 |
-53%
|
| 5-Year Average | 30.3 | ₩2 571.84 |
-62%
|
| Industry Average | 19.6 | ₩1 667.55 |
-76%
|
| Country Average | 12.5 | ₩1 066.03 |
-84%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
Kyongbo Pharmaceutical Co Ltd
KRX:214390
|
163B KRW | 80.2 | 894.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 29 | 40.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 21.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.6 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 11.6 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 10.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.9 | 16.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.8 |
| Median | 12.5 |
| 70th Percentile | 23.2 |
| Max | 13 874.5 |
Other Multiples
Kyongbo Pharmaceutical Co Ltd
Glance View
KYONGBO PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Asan, Chungcheongnam-Do. The company went IPO on 2015-06-29. The firm distributes its products within domestic market and to overseas markets including China Japan and Europe.
